be identified in the cytoplasm of chronic myelogenous leukemia cells, which contained no functional dihydrofolate reductase activity. Its concentration was stoichiometric to the volume of cytoplasm assayed and paralleled the standard curve obtained with purified enzyme, indicating that this protein in the human cells is antigenically similar to the homologous antigen. The concentration ofthis immunoreactive protein in the cytoplasm ofhuman leukemia and normal leukocytes in all instances greatly exceeded the concentration of functional dihydrofolate reductase, which was measured by the binding of [3H] methotrexate. This nonfunctional immunoreactive protein in the cytoplasm and cytosol from two different samples of chronic myelogenous leukemia cells analyzed by gel filtration had an apparent molecular weight of 41,000, which is twice the molecular weight of the functional enzyme.
Cells in the proliferative phase of cell growth generally have greater activity of dihydrofolate reductase (DHFR; tetrahydrofolate dehydrogenase; 5,6,7,8-tetrahydrofolate:NADP+ oxidoreductase, EC 1.5.1.3) than cells in the stationary phase (1, 2) because this enzyme is required to regenerate tetrahydrofolate (H4folate) from dihydrofolate (H2folate), the oxidation product of the de novo pathway for the methylation of dUMP to form TMP (3) . Although this enzyme is active in many tumors and leukemias of both animal and human origin (4) (5) (6) (7) (8) (9) (10) , little or no DHFR activity has also been observed in some human cancers and leukemias (10) (11) (12) and in proliferating lymphocytes (13) , even when activity of the enzyme was measured by extremely sensitive radioassay procedures (14, 15 ). It appears likely that such cells were rapidly degrading the enzyme, because after exposure to methotrexate (MTX) DHFR could subsequently be detected (10, 16) , indicating that the enzyme-inhibitor complex is resistant to intracellular proteolysis.
Additional evidence for a nonfunctional form of DHFR in some cells is the recent observation from this laboratory that the cytoplasm from chronic myelogenous leukemia (CML) cells contains a protein with immunologic crossreactivity with purified active DHFR from L1210 murine leukemia cells, even though the CML cells were devoid of catalytic DHFR activity (17) . We now report our studies to measure by quantitative radioimmunoassay (RIA) the concentration ofthis nonfunctional immunoreactive enzyme protein in the cytoplasm of leukemia and normal leukocytes and to characterize by gel column chromatography this protein in two samples of CML cells.
MATERIALS AND METHODS
[3H]MTX (specific activity greater than 5 Ci/mmol; 1 Ci = 3.7 X 101 becquerels), [3H]folic acid (specific activity 24 Ci/ mmol), and carrier-free sodium ['"I]iodide were purchased from Amersham.
NADPH, folic acid, H2folate, phenylmethylsulfonyl fluoride, and bovine serum albumin were purchased from Sigma. Sephadex G-200 was purchased from Pharmacia. Trasylol was obtained from Mobay (New York). Protamine sulfate was purchased from U.S. Biochemical (Cleveland, OH). Dowex AG1-X8 was purchased from Bio-Rad. Antiserum to rabbit gamma globulin was purchased from Miles. All other chemicals were of reagent grade. MTX was obtained through the courtesy of Lederle Laboratories (Pearl River, NY) and purified by the method of Gallelli and Yokoyama (18) .
Purification of DHFR. A modification of the procedure of Kaufman and Kemerer (19) was used to purify DHFR from calf liver. Approximately 250 g of liver was minced and then suspended in 3 vol of 0.1 M potassium phosphate buffer (pH 7.4) and homogenized in a Waring blender for 4 min. This and all subsequent procedures were carried out at a temperature below 4°C. After centrifugation at 13,000 x g for 30 min the supernatant solution was passed through glass wool and treated with 0.2 volof 2% protamine sulfate. After 15 min the precipitate was pelleted by centrifugation and the pH of the supernate was reduced to 5.5 by dropwise addition of 1 M HC1. The precipitate was pelleted by centrifugation at 13,000 X g for 30 min and the supernatant solution was neutralized with 1 M NaOH. Zinc sulfate was then added to a final concentration of 16 mM and the precipitate that formed was removed by centrifugation. Crystalline ammonium sulfate was then added to the supernatant solution to a concentration of50% of saturation (precipitate discarded) and then 80% of saturation. This final precipitate was dissolved in 0.1 M potassium phosphate buffer (pH 7.4). Undissolved particulate material was removed by centrifugation at 105,000 X g for 60 min and the clear supernate containing 50 AM NADPH was passed through an affinity column composed of Sepharose-MTX prepared by the method of Kaufman and Pierce (20) . After thorough washing with potassium phosphate buffer (0.5 M and 0.05 M, pH 7.4) until the absorbance at 280 nm was zero, the enzyme was eluted with a solution of H2folate (0.2 mg/ml) prepared in 0.5 M dibasic potassium phosphate (pH 8.9). Five fractions (2 ml each) were collected and dialyzed separately against 0.05 M potassium phosphate buffer (pH 7.4) to remove the H2folate. The activity ofthe enzyme was determined by the reduction of [3H]folic acid (14) (15) . Protein was measured by the method of Lowry et aL (22) . The homogeneity of the enzyme was determined by polyacrylamide gel electrophoresis as described by Maurer (23 of NADPH were then added.to each incubation mixture and the reaction volume was brought to 0.5 ml with 0.05 M sodium citrate (pH 7.4) containing 1 mg of bovine serum albumin. The reaction mixtures were incubated for 30 min at room temperature and the free [3H]MTX was then separated by the addition of0.4 ml ofa 1% suspension ofdextran-coated charcoal (15) . The radioactivity in the supernatant solution representing the bound [3H]MTX was determined by using a liquid scintillation counter as described (15) .
RIA. The purified DHFR was labeled with ['5I]iodine by the chloramine-T method of Greenwood et al. (24) . The iodination reaction was limited to 15 sec and the free FI-was separated from "2I-labeled DHFR by exhaustive dialysis. After dialysis the sample was filtered through Sephadex G-75 and only the "2I-labeled enzyme in the fractions corresponding to 'the elution of purified DHFR was used in the RIA.
A sequential procedure was used for the RIA in order to achieve maximal sensitivity. A dilution of the antiserum that bound 40-50% of the "2I-labeled enzyme was incubated with the standard purified enzyme, or the sample being assayed, in a total volume of 500 ,ul of 0.02 M Tris HCl buffer, pH 7.4, containing 250 kallikrein inhibitor units of Trasylol for 48 hr at 40C. 125I-Labeled DHFR was then added (100 A1l containing approximately 15,000 cpm) and the reaction mixtures were incubated for an additional 16 hr at 40C. The antibody-bound 15I-labeled DHFR was precipitated by the addition of 10 ,ul of antirabbit gamma globulin, followed in 20 min by 100 ,ul of 10% polyethylene glycol. After 15 min, the precipitate was pelleted by centrifugation, washed once with cold 0.02 M Tris-HCl buffer (pH 7.4), and assayed in a Beckman Autogamma counter. Sufficient counts were accumulated for a counting error of ± 3% or less.
Preparation of Leukocyte Cytoplasm and Cytosol. Heparintreated peripheral blood was mixed with an equal volume of3% dextran in 0.15 M NaCl and the erythrocytes were allowed to sediment at 4°C. The leukocytes in the supernatant plasma were than pelleted by centrifugation at 1400 X g for 15 min at 4°C. Any remaining erythrocytes in the pellet were lysed by the addition of 3 vol of cold distilled water followed in 30 sec by the addition of 0.6 M NaCl. The leukocytes were washed three times with cold 0.15 M NaCl, suspended in 3 vol of 0.05 M citrate buffer (pH 7.4), and stored at -70°C. Before assaying, the cell suspension was thawed and frozen an additional two times and the cell particulate material was separated by centrifugation at 30;000 x g for 30 min to obtain the cytoplasm and 105,000 X g for 60 min to obtain the cytosol. These preparations 'were analyzed for immunoreactive DHFR by RIA, for active DHFR by [3H]MTX binding (15) , and for protein concentration by the 'method of Lowry et aL (22) .
Gel Column Chromatography. Sephadex G-75 was equilibrated with 0.02 M Tris HCl buffer (pH 7.4) containing 0.13 M NaCl and packed in a column 1.5 X 75 cm. One Sephadex G-75 column was prepared with the buffer containing 0.05% Triton X-100. The cytoplasm (2 ml) was applied to the column and eluted at a flow rate of36 ml per hour, collecting 2-ml fractions. A Sephadex G-200 column (2.5 x 100 cm) was prepared with 0.05 M Tris HCl (pH 7.4) containing Trasylol at 1000 kallikrein inhibitor units/liter, phenylmethylsulfonyl fluoride at 3.5 mg/ liter, and 0.02% sodium azide. Two milliliters of cytosol was applied to the column and eluted at aflow rate of12 ml per hour, collecting 1.4-ml fractions. All fractions were assayed for immunoreactive DHFR by RIA and for functional enzyme by the binding of [3H]MTX (15) .
RESULTS
The-purified DHFR appeared homogeneous by polyacrylamide gel electrophoresis and by immunochemical analysis. A single precipitin line appeared when the purified homologous enzyme was subjected to agar immunodiffusion against the rabbit antiserum, and no line appeared when the partially purified extract ofthe liver was run against this antiserum (data not shown). The antiserum stoichiometrically inhibited the binding of [3H]MTX by the purified calf liver DHFR (Fig. 1) .
The purified enzyme was chromatographed through Sephadex G-75, and each fraction was assayed for immunoreactive protein (see below) and for enzymatic reduction of [3H]folic acid to H4folate. The immunoreactive protein and catalytically active enzyme coeluted in the same fractions (Fig. 2) just before the marker protein, cytochrome c (Mr 13,000). A small peak of immunoreactive material eluted just within the total volume ofthe column and represents some small polypeptide fragments formed during storage of the purified enzyme.
The dose-response curve for the RIA using the purified DHFR as the competing standard antigen is shown in Fig. 3 (Fig. 2) . The addition of Triton X-100 to the buffer during preparation of the column and for the elution of the cytoplasm did not alter the elution of the immunoreactive DHFR in the void volume (Fig. 5, middle chromatogram) , indicating that its large size is, not likely to be the result of hydrophobic aggregation.
A more precise estimate of molecular size was obtained by chromatography through Sephadex G-200 (Fig. 5, right of DHFR in the CML cytoplasm has low affinity for these antibodies.
The big species ofimmunoreactive but nonfunctional enzyme -that eluted from Sephadex G-200 (1982) 649 tional immunoreactive protein in all the leukocytes has the same apparent molecular weight as the nonfunctional protein in the CML cells, but it is likely to be similar in the other leukemia cells.
The nature ofthis big species ofimmunoreactive DHFR must be further characterized and its relationship to active DHFR must be established, but it is not likely that an inactive protein that is larger than the functional enzyme is a degradation product of the active molecule.
The big species of nonfunctional DHFR is in the cytosol of the CML cells (105,000 x g supernate) and the failure ofTriton X-100 to reduce its size indicates that it is not a product of hydrophobic aggregation of the active enzyme. The fact that it is precisely twice the size of the active enzyme suggests that it is a dimer, but alternative possibilities must also be considered. For example, it could be a complex of DHFR with a carrier protein as described for adenine deaminase (26) , or it could be an immunoreactive form of the enzyme attached to a fragment of cytoplasmic RNA (27) . However, in such instances it would be an unlikely coincidence for this inactive species to have a molecular weight exactly twice that of the active enzyme.
We have not been able to activate this nonfunctional big species of DHFR from the CML cytoplasm with KC1, urea, guanidine hydrochloride, or excess NADPH, compounds that have been reported to increase the activity or alter the electrophoretic mobility of DHFR (28) (29) (30) (31) (32) . However, physiologic activation might require, in addition to NADPH and substrate, some other intracellular factor(s) that are only present in mitotically active cells. CML leukemia cells from the peripheral blood contain only a small percentage ofcells capable ofmitosis, and such a heterogeneous population of cells, therefore, would not be a good model to study for such an activation mechanism.
The biological significance of this immunoreactive form of DHFR merits some discussion even though it is speculative at this time. It will be important, for example, to determine if the concentration or molecular properties of this nonfunctional big species of the enzyme differ in normal and cancer cells, even though we found a similar concentration in leukemia cells and normal leukocytes. It will also be important to determine whether the concentration of this protein varies during logarithmic and stationary growth of cells, as does active DHFR (2, 4) . Ifthis big species ofenzyme protein is a natural precursor of active DHFR, then the perturbation of the conditions necessary for activation could be the biochemical basis ofinherited or acquired disorders of folate metabolism, some of which are now poorly understood.
Active DHFR is the target enzyme for inhibition by the antifolate drugs, and manipulation of the conditions required to transform a high molecular weight inactive molecule into the active enzyme would have obvious application in cancer chemotherapy. In addition, if the density of malignant cells containing this protein is greater in a tumor than the density of normal cells in the surrounding tissue, then radiolabeled antibodies to this protein may be of value in localizing such tumors in vivo (33) .
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